Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.

BMC cancer - 12 Mar 2020

Eoh Kyung Jin, Kim Hye Min, Lee Jung-Yun, Kim Sunghoon, Kim Sang Wun, Kim Young Tae, Nam Eun Ji

Abstract excerpt

BACKGROUND: Poly (ADP-ribose) polymerase inhibitors targeting BRCA1/2 mutations are available for treating patients with high-grade serous ovarian cancer. These treatments may be more appropriately directed to patients who might respond if the tumor tissue is additionally tested by next-generation sequencing with a multi-gene panel and Sanger sequencing of a blood sample. In this study, we compared the results...

Topics

Join the communities discussing this publication.

BRCA1 Protein
BRCA2 Protein
Cystadenocarcinoma, Serous
Germ-Line Mutation
High-Throughput Nucleotide Sequencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Neoplasm Grading

Ovarian Neoplasms

Poly(ADP-ribose) Polymerase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 32164585
DOI: 10.1186/s12885-020-6693-y
PMCID: PMC7069205

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.PMID 32164585Read ↗

Validation of multi-gene panel next-generation sequencing for the detection of BRCA mutation in formalin-fixed, paraffin-embedded epithelial ovarian cancer tissues.Semantic proximity Read ↗

BRCA1/2 NGS Somatic Testing in Clinical Practice: A Short Report.Semantic proximity Read ↗

Clinical implications of next-generation sequencing-based panel tests for malignant ovarian tumors.Semantic proximity Read ↗

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.Semantic proximity Read ↗

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.Semantic proximity Read ↗

Germline and somatic variants in ovarian carcinoma: A next-generation sequencing (NGS) analysisSemantic proximity Read ↗

Detection of somatic BRCA1/2 mutations in ovarian cancer - next-generation sequencing analysis of 100 cases.Semantic proximity Read ↗

Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer.Semantic proximity Read ↗

Exploring alternatives to tumor tissue for BRCA1/2 next-generation sequencing testing in high-grade serous ovarian cancer: A 34-case series of malignant ascites.Semantic proximity Read ↗

NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial.Semantic proximity Read ↗

Detection of BRCA1/2 mutations in circulating tumor DNA from patients with ovarian cancerSemantic proximity Read ↗

High-grade serous ovarian carcinoma and detection of inactivated BRCA genes from biopsy material of Slovak patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.